As global markets navigate a complex landscape of inflation data and trade negotiations, Asian stock markets have shown resilience, with notable advances in Japan and China. Despite the term ‘penny stocks’ evoking images of past trading eras, these smaller or newer companies continue to offer intriguing investment opportunities when backed by solid financials. This article explores three such penny stocks in Asia that stand out for their financial strength and potential for growth.

Name

Share Price

Market Cap

Financial Health Rating

Food Moments (SET:FM)

THB4.02

THB3.95B

★★★★★☆

JBM (Healthcare) (SEHK:2161)

HK$2.90

HK$2.38B

★★★★★★

Lever Style (SEHK:1346)

HK$1.47

HK$977.26M

★★★★★★

TK Group (Holdings) (SEHK:2283)

HK$2.49

HK$2.09B

★★★★★★

CNMC Goldmine Holdings (Catalist:5TP)

SGD0.625

SGD255.33M

★★★★★☆

Goodbaby International Holdings (SEHK:1086)

HK$1.17

HK$1.99B

★★★★★★

Yangzijiang Shipbuilding (Holdings) (SGX:BS6)

SGD2.87

SGD11.33B

★★★★★☆

Ekarat Engineering (SET:AKR)

THB0.96

THB1.4B

★★★★★★

Livestock Improvement (NZSE:LIC)

NZ$0.95

NZ$135.23M

★★★★★★

Rojana Industrial Park (SET:ROJNA)

THB4.74

THB9.62B

★★★★★★

Click here to see the full list of 971 stocks from our Asian Penny Stocks screener.

Let’s explore several standout options from the results in the screener.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Brii Biosciences Limited develops therapies for infectious and central nervous system diseases in China and the United States, with a market cap of HK$1.73 billion.

Operations: The company’s revenue is generated from its Biotechnology (Startups) segment, amounting to CN¥54.99 million.

Market Cap: HK$1.73B

Brii Biosciences Limited, with a market cap of HK$1.73 billion, is navigating the biotech sector with a focus on infectious and central nervous system diseases. The company recently entered into a strategic agreement with Joincare Pharmaceutical Group for BRII-693, securing an upfront payment and potential milestone payments. Despite being pre-revenue with CN¥54.99 million in revenue from its biotechnology segment, Brii Bio maintains strong financial health; its short-term assets (CN¥2.4 billion) comfortably cover both short- and long-term liabilities. However, it remains unprofitable with negative return on equity and no forecasted profitability within the next three years.

SEHK:2137 Debt to Equity History and Analysis as at Aug 2025

SEHK:2137 Debt to Equity History and Analysis as at Aug 2025

Simply Wall St Financial Health Rating: ★★★★★★

Story Continues